期刊文献+

1例2型糖尿病肾病尿微量白蛋白期患者的循证治疗 被引量:1

1例2型糖尿病肾病尿微量白蛋白期患者的循证治疗
下载PDF
导出
摘要 目的:以循证医学的方法为1例2型糖尿病肾病尿微量白蛋白期患者确定治疗目标和治疗方案。方法:根据患者的情况,提出临床问题,从Cochrane图书馆(2009年第4期)、Medline(Pubmed网站1998-2009)及EMBASE(1998-2009)上进行检索,对所获证据进行评价,制定治疗方案。结果:共检索出与不同临床问题相关的随机对照实验17篇,系统评价或meta-分析11篇。证据显示通过对影响糖尿病肾病发展的因素进行治疗,可明显提高治疗效果,经过半年的随访后证实,该方案适合患者。结论:采取循证治疗的方法,为2型糖尿病肾病尿微量白蛋白期患者确定治疗目标和治疗方案,能有效延缓病情发展。 Objective To make an individulized treatment for a patient diagnosed type 2 diabetic nephropathy with microalbuminuria with the method of evidence - based medicine.Methods According to the clinical problems of the patient, evidence was searched from Cochrane Library(fourth issue, 2009), Medline(PubMed 1998- 2009) and EMBASE( 1998- 2009) for the decision- making treatment according to the search strategy. Rest/Its There are 17 RCTs and II systematic reviews or metaanalysis that were identified about clinical problems. The evidence indicated that the treatment efficacy has been improved after the progression of diabetic nephropathy inthe intervention. And after a half of year followup, the treatment plan was proved optimal. Conclusion The progression of a patient diagnosed type 2 diabetic nephropathy with microalbuminuria can be delayed by determining an individulized treatment plan according to the evidencebased methods.
作者 陈冠亚
出处 《内蒙古中医药》 2011年第3期178-180,共3页 Inner Mongolia Journal of Traditional Chinese Medicine
关键词 糖尿病肾病 微量蛋白尿 循证治疗 diabetic nephropathy micmalbuminuria evidence- based treatment
  • 相关文献

参考文献9

  • 1Nakamura T,Sugaya T,Kawagoe Y,et al.Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in petients with early diabetic nephropathy[J].Diabetes Care,2005,28 (11):2728-2732.
  • 2UK Prospective Diabetes Stuay (UKPDS)Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38[J].BMJ,1998,317 (7160):703-713.
  • 3Ansquer JC,Foucher C,Rattier S,et al.Fenofibrate reducesprogression to microalbuminuria over 3 years in a placebocontrolleddstuay in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS)[J].Am J Kiadney Dis,2005,45 (3):485-493.
  • 4Schrier RW,Estscio RO,Ealer A,et al.Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria,retinopathy and strokes[J].Kidney Int,2002,61(3):1066- 1097.
  • 5Ng DP,Tai BC,Koh D,et al.Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy:a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects [J].Diabetologia,2005,48(5):1008-1016.
  • 6de Mello VD,Zelmanovitz T,Azevedo MJ,et al.Long-term effect of a chicken -based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria[J].J Ren Nutr,2008,18(5):440-447.
  • 7Strippoli GF,Craig M,Deeks JJ,et al.Effects of angiotensin converting enzyme inhibitors and angiotensinⅡ receptor antagonists on mortality and renal outcomes in diabetic nephropathy:systematic review [J].BMJ,2004,329(7470):828.
  • 8Strippoli GF,Craig MC,Schena FP,et al.Role of blood pressure targets and specific antihypertensive agents used to prevent diabelic nephropathy and delay its progression[J].J Am Soc Nephhrol,2006,17(42):S153-5.
  • 9Critchley JA,Zhao HL,Tomlinson B,Leung W,Thomas GN,Chan JC,Cockram CS.Management of nephropathy in patients with type 2 diabetes[J].Chinese Medical Journal,2002(1):129-135. 被引量:12

二级参考文献2

  • 1T. Fujisawa,H. Ikegami,Y. Kawaguchi,Y. Hamada,H. Ueda,M. Shintani,M. Fukuda,T. Ogihara. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy[J] 1998,Diabetologia(1):47~53
  • 2Dr. K. S. L. Lam,I. K. P. Cheng,E. D. Janus,R. W. C. Pang. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy[J] 1995,Diabetologia(5):604~609

共引文献11

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部